REG - Concepta PLC - Change of Adviser

MyhealthcheckedAnnouncement

22/07/2020 07:00

RNS Number : 6811T
  
Concepta PLC
  
22 July 2020
  
 

Concepta PLC
("Concepta" or the "Company") 
 
Change of Adviser 
 
Concepta PLC (AIM: CPT), the personalised healthcare company, announces the appointment of Oberon Capital, part of the Oberon Investments Ltd group, as joint broker with immediate effect.
 



Concepta plc


www.conceptaplc.com




Penny McCormick, Chief Executive Officer


via Walbrook PR




Maddy Kennedy, Chief Financial Officer


















SPARK Advisory Partners Limited (NOMAD)


Tel: +44 (0)20 3368 3550




Neil Baldwin 


















Novum Securities (Joint Broker)


Tel: +44 (0)20 7399 9400




Colin Rowbury


















Oberon Capital Ltd (Joint Broker)


Tel: +44 (0)203 179 5344




Mike Seabrook


mikeseabrook@oberoninvestments.com














Walbrook PR Ltd (Media & Investor Relations)


Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com




Paul McManus


Mob: +44(0)7980 541 893 



 
 
About Concepta PLC (www.conceptaplc.com) 
 
Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product MYLO, targeted at the personalized mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.
 
MYLO is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of MYLO is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.
 
The Company has received CE-mark certification for MYLO and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2020 and 2021. 
 
MYLO is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
APPEAKXFALXEEFA